Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib in Progressive, Metastatic Medullary Thyroid Cancer
NCT01896479Phase 4Active, not recruiting
- Sponsor
- Exelixis, Inc.
- Start
- Feb 2015
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 4 trial of cabozantinib in Medullary Thyroid Cancer (MTC), sponsored by Exelixis, Inc.. Started Feb 2015; status: active, not recruiting.
02
Drugs
cabozantinib
03
Conditions
Medullary Thyroid Cancer (MTC)
Beyond the preview
Go deeper on NCT01896479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01896479.